Prostate Disease Articles & Analysis
30 news found
Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
For those with tumors harboring a specific gene fusion, there is a greater risk of recurrence and higher all-cause and prostate cancer-specific mortality. One way to reduce the burden of this disease on men and their families is to diagnose this highly curable cancer long before it hits a problematic stage. ...
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access ...
Of the 10 evaluable patients with ovarian clear cell carcinoma, four had a partial response and three had stable disease. Of the eight evaluable patients with metastatic castration-resistant prostate cancer, five had stable disease. ...
This recommendation is another step in our mission to redefine what it means to live with prostate cancer across various stages of the disease.” “Despite significant advances, for many men with mHSPC, disease progression and the onset of debilitating symptoms remain commonplace. ...
ByBayer AG
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the detection and clinical management of men >45 years of age at risk for prostate cancer. "An estimated 268,490 men will be diagnosed with prostate cancer in 2022 according to the American Cancer Society. miR Scientific's vision is to ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
“For decades, GE Healthcare has proudly equipped clinicians with advanced MRI technologies to visualize and diagnose prostate cancer. Now, we are proud to enable access to a new tool to help clinicians treat this disease under precise MRI guidance: Profound’s TULSA-PRO®. This noninvasive MRI-guided therapy technology is customized to each patient ...
In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.(1) At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...
ByBayer AG
Stephen Neidle Session Title: New Chemotherapy Agents Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT Abstract Number: 4068 Title: “The potent quadruplex-binding compound SOP1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic ...
However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 points greater across all follow-up visits in the Aquablation group compared to the TURP group (p=.0123). ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
” Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Combining both cystoscopic visualization and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. ...
We look forward to further exploring this approach against this disease, including those tumors that have shown little to no response to standard chemotherapeutic treatments such as gemcitabine,” added Professor Neidle. ...
Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and ...
FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. “Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems for the management of prostate cancer and other diseases and health conditions. Qualigen’s management has significant experience in drug and medical device development, ...